Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer
Metrics: PDF 708 views | HTML 763 views | ?
Feng Wei1,3,4, Fan Yang2,3,4, Jing Li1,3,4, Yu Zheng2,3,4, Wenwen Yu1,3,4, Lili Yang1,3,4, Xiubao Ren1,2,3,4
1Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China
2Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China
3National Clinical Research Center for Cancer, Tianjin, PR China
4Tianjin Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, PR China
Xiubao Ren, email: firstname.lastname@example.org
Keywords: soluble Toll-like receptor 4 (sTLR4), non-small cell lung cancer (NSCLC), high-mobility group box 1 (HMGB1), biomarker
Received: January 11, 2016 Accepted: May 05, 2016 Published: May 20, 2016
This study investigated the clinical significance of serum soluble Toll-like receptor 4 (sTLR4) in non-small cell lung cancer (NSCLC). A total of 54 NSCLC patients and 13 healthy volunteers were enrolled from January 2012 to December 2013. The patients with NSCLC were characterized by significantly higher serum levels of sTLR4 compared with those in healthy controls (P < 0.01). A positive correlation between serum sTLR4 and tumor stage was found in patients with stages I–III NSCLC. However, serum sTLR4 in patients with metastatic NSCLC was significantly decreased compared with those with stage III NSCLC (P < 0.05). Furthermore, low serum sTLR4 was identified as a prognostic marker for poor survival of early-stage NSCLC patients who received surgical resection. In conclusion, our present study identified sTLR4 as a potential serum biomarker of NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.